Ashkan Abbey, MD

Data suggests the candidate can reduce the number of injections and treatment burden for patients

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.